P
Paul J. Kurtin
Researcher at Mayo Clinic
Publications - 253
Citations - 17173
Paul J. Kurtin is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Lymphoma & Amyloidosis. The author has an hindex of 70, co-authored 247 publications receiving 15778 citations. Previous affiliations of Paul J. Kurtin include University of Iowa.
Papers
More filters
Journal ArticleDOI
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
Stefano Monti,Kerry J. Savage,Jeffery L. Kutok,Friedrich Feuerhake,Paul J. Kurtin,Martin C. Mihm,Bingyan Wu,Laura Pasqualucci,Donna Neuberg,Ricardo C.T. Aguiar,Paola Dal Cin,Christine Ladd,Geraldine S. Pinkus,Gilles Salles,Nancy L. Harris,Riccardo Dalla-Favera,Thomas M. Habermann,Jon C. Aster,Todd R. Golub,Todd R. Golub,Margaret A. Shipp +20 more
TL;DR: Tumor microenvironment and host inflammatory response as defining features in DLBCL are identified and rational treatment targets in specificDLBCL subsets are suggested.
Journal ArticleDOI
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
Kerry J. Savage,Stefano Monti,Jeffery L. Kutok,Giorgio Cattoretti,Donna Neuberg,Laurence de Leval,Paul J. Kurtin,Paola Dal Cin,Christine Ladd,Friedrich Feuerhake,Ricardo C.T. Aguiar,Sigui Li,Gilles Salles,Françoise Berger,Wen Jing,Geraldine S. Pinkus,Thomas M. Habermann,Riccardo Dalla-Favera,Nancy L. Harris,Jon C. Aster,Todd R. Golub,Margaret A. Shipp +21 more
TL;DR: A molecular link between MLBCL and cHL and a shared survival pathway is identified and a classifier of these diseases is developed.
Journal ArticleDOI
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
Robert A. Kyle,Ellen D. Remstein,Terry M. Therneau,Angela Dispenzieri,Paul J. Kurtin,Janice M. Hodnefield,Dirk R. Larson,Matthew F. Plevak,Diane F. Jelinek,Rafael Fonseca,Lee Joseph Melton,S. Vincent Rajkumar +11 more
TL;DR: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Journal ArticleDOI
Lymphoid Neogenesis in Rheumatoid Synovitis
Seisuke Takemura,Andrea Braun,Cynthia S. Crowson,Paul J. Kurtin,Robert H. Cofield,William M. O'Fallon,Jörg J. Goronzy,Cornelia M. Weyand +7 more
TL;DR: Multivariate logistic regression analysis of tissue cytokines and chemokines identified two parameters, in situ transcription of lymphotoxin (LT)-β and of B lymphocyte chemoattractant (BLC; BLC/CXCL13), that were predictors for FDC recruitment and synovial GC formation.
Journal ArticleDOI
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Thomas E. Witzig,Susan Geyer,Irene M. Ghobrial,David J. Inwards,Rafael Fonseca,Paul J. Kurtin,Stephen M. Ansell,R. F. Luyun,Patrick J. Flynn,Roscoe F. Morton,Shaker R. Dakhil,Howard M. Gross,Scott H. Kaufmann +12 more
TL;DR: It is demonstrated that agents that selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit and single-agent temsirolimus has substantial antitumor activity in relapsed MCL.